Abstract：
Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality. Important risk factors for the development of HFpEF are similar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions frequently coexist and thus is a distinct phenotype or a marker for advanced HF. Many patients with severe, symptomatic atrial secondary TR have been enrolled in current transcatheter device trials, and may represent patients at an advanced stage of HFpEF. Management of HFpEF thus may affect the pathophysiology of TR, and the physiologic changes that occur following transcatheter treatment of TR, may also impact symptoms and outcomes in patients with HFpEF. This review discusses these issues and suggests possible management strategies for these patients.
摘要：
射血分数保留的心力衰竭（HFpEF）与高发病率和死亡率相关。HFpEF发展的重要危险因素与三尖瓣反流（TR）进展的危险因素相似，并且这两种情况经常共存，因此是晚期HF的独特表型或标志物。许多严重的患者，有症状的心房继发性TR已纳入当前的经导管器械试验，并且可能代表处于HFpEF晚期的患者。因此，HFpEF的管理可能会影响TR的病理生理学，以及经导管治疗TR后发生的生理变化，也可能影响HFpEF患者的症状和预后。这篇综述讨论了这些问题，并为这些患者提出了可能的管理策略。
